2.6.1.16 (2S)-2-amino-3-(([(2R,3R)-3-benzoyloxiran-2-yl]carbonyl)amino)propanoic acid - 42333 2.6.1.16 (2S)-2-amino-3-([(2E)-4-oxo-4-phenylbut-2-enoyl]amino)propanoic acid - 42335 2.6.1.16 (2S)-2-amino-3-([(2E)-4-oxopent-2-enoyl]amino)propanoic acid - 42336 2.6.1.16 (2S)-3-(([(2R,3R)-3-acetyloxiran-2-yl]carbonyl)amino)-2-aminopropanoic acid - 42334 2.6.1.16 (3R,4S)-4-(methylamino)-1-phenylpent-1-en-3-ol - 253064 2.6.1.16 (4S)-2-methyl-2-phenylpentane-1,4-diol - 253061 2.6.1.16 1'-N-methyl spiro[2'.2'']-acenaphthyleno-3'-cholestrylcarboxylate pyrrolidine - 251700 2.6.1.16 1'-N-methyl spiro[2'.2'']-indane-1'',3''-dione-3'-cholestrylcarboxylate pyrrolidine - 251701 2.6.1.16 1'-N-methyl spiro[2'.3'']-(4'',7''-dichloro)-oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251702 2.6.1.16 1'-N-methyl spiro[2'.3'']-(5'',7''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251703 2.6.1.16 1'-N-methyl spiro[2'.3'']-(5''-bromo)-oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251704 2.6.1.16 1'-N-methyl spiro[2'.3'']-(N-methyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251705 2.6.1.16 1'-N-methyl spiro[2'.3'']-(N-phenyl)-oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251706 2.6.1.16 1'-N-methyl spiro[2'.3'']oxindolo-3'-cholestrylcarboxylate pyrrolidine - 251707 2.6.1.16 1,1'-dithiodiformamidine irreversible inhibition 16896 2.6.1.16 1,1'-[1,3,4-thiadiazole-2,5-diylbis[sulfanediyl(1-oxoethane-2,1-diyl)]]ditetrahydropyridazine-3,6-dione - 209146 2.6.1.16 1,2-anhydrohexitol 6-phosphate mixture of the four diastereoisomers. Irreversible inactivation. D-fructose 6-phosphate and 2-amino-2-deoxyglucitol protect, L-glutamine does not 112149 2.6.1.16 1-methyl 8-(2-oxopropyl) (2E,7S)-7-amino-4-oxooct-2-enedioate ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans 209122 2.6.1.16 1-methyl 8-[(2R)-3-oxobutan-2-yl] (2E,7S)-7-amino-4-oxooct-2-enedioate ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans 209123 2.6.1.16 2,2'-(1,3,4-thiadiazole-2,5-diyldisulfanediyl)bis[N-(pyrrolidin-1-yl)acetamide] - 209147 2.6.1.16 2-(4-hydroxyphenyl)-4-(4-nitrophenylimino)chroman-5,7-diol - 253065 2.6.1.16 2-amino-2-deoxy-D-glucitol 6-phosphate - 18225 2.6.1.16 2-amino-2-deoxy-D-glucitol-6-phosphate inhibitor of the sugar isomerising domain 11746 2.6.1.16 2-amino-2-deoxy-D-glucitol-6-phosphate - 11746 2.6.1.16 2-amino-2-deoxy-D-glucitol-6-phosphate IC50: 0.056 mM 11746 2.6.1.16 2-amino-2-deoxy-D-glucitol-6-phosphate dimethyl ester - 62538 2.6.1.16 2-amino-2-deoxy-D-mannitol 6-phosphate - 25106 2.6.1.16 2-amino-2-deoxy-D-mannitol-6-phosphate exhibits stronger affinity for the sugar-binding site of GlcN-6-P synthase than 2-amino-2-deoxy-D-glucitol-6-phosphate 36409 2.6.1.16 2-amino-2-deoxy-D-mannitol-6-phosphate - 36409 2.6.1.16 2-Amino-2-deoxyglucitol 6-phosphate competitive with respect to D-fructose 6-phosphate 19909 2.6.1.16 3-(tert-butoxycarbonyl)-6-(3-benzoylprop-2-yl)phenol - 253063 2.6.1.16 4,4'-dithiodipyridine inactivation reversed by dithiothreitol. Competitive with respect to L-glutamine. Non-competitive with respect to D-fructose 6-phosphate 6845 2.6.1.16 4-(1,3-dihydroxypropan-2-ylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol - 252089 2.6.1.16 4-(2-chlorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol - 252114 2.6.1.16 4-(2-fluorophenylimino)-2-(4-hydroxyphenyl)chroman-5,7-diol - 252115 2.6.1.16 4-(furan-2-ylcarbonyl)-3-hydroxy-5-(4-phenoxyphenyl)-1-(pyridin-3-ylmethyl)-1,5-dihydro-2H-pyrrol-2-one 20% inhibition at 0.1 mM 134765 2.6.1.16 4-Glutamylhydroxamate - 46148 2.6.1.16 5,5'-dithionitrobenzoic acid irreversible inhibition 13388 2.6.1.16 5,5'-dithionitrobenzoic acid inactivation reversed by dithiothreitol 13388 2.6.1.16 5-phospho-D-arabinoamide - 24432 2.6.1.16 6,6'-Dithiodinicotinic acid irreversible inhibition 9307 2.6.1.16 6,7-bis(2-methoxyphenyl)-10-methyl-1,4,7,12-tetrahydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine 70% inhibition at 0.1 mM 134766 2.6.1.16 6-diazo-5-oxo-L-norleucine - 839 2.6.1.16 6-diazo-5-oxo-L-norleucine competitive with respect to L-glutamine 839 2.6.1.16 6-diazo-5-oxo-L-norleucine inhibitor of the glutamine binding site 839 2.6.1.16 6-diazo-5-oxo-L-norleucine 2 mM 839 2.6.1.16 7-methoxy-2,3-dihydro-2-phenyl-4 quinolone - 253062 2.6.1.16 8-(3,3-dimethyl-2-oxobutyl) 1-methyl (2E,7S)-7-amino-4-oxooct-2-enedioate ester derivative of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid, potent inhibitory activity against fungal glucosamine-6-phosphate synthase, good antifungal activity against Candida albicans 209124 2.6.1.16 Aaptamine IC50: 0.12 mM 36208 2.6.1.16 albizziin - 10572 2.6.1.16 amitrole IC50: 0.1 mM 22086 2.6.1.16 anticapsin - 5519 2.6.1.16 anticapsin L-glutamine protects, irreversible inhibition 5519 2.6.1.16 anticapsin competitive 5519 2.6.1.16 anticapsin inhibitor of the glutamine binding site 5519 2.6.1.16 arabinose oxime 5-phosphate inhibitor of the sugar isomerising domain 135485 2.6.1.16 azaserine weak 1861 2.6.1.16 azaserine - 1861 2.6.1.16 catechin - 1437 2.6.1.16 cholest-5-en-3-yl 1,3-dioxo-1,1',2',3,5',6',7',7'a-octahydrospiro[indene-2,3'-pyrrolizine]-2'-carboxylate - 252385 2.6.1.16 cholest-5-en-3-yl 1-methyl-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252386 2.6.1.16 cholest-5-en-3-yl 2-oxo-1',2',5',6',7',7'a-hexahydro-2H-spiro[acenaphthylene-1,3'-pyrrolizine]-2'-carboxylate - 252387 2.6.1.16 cholest-5-en-3-yl 2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252388 2.6.1.16 cholest-5-en-3-yl 2-oxo-1-phenyl-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252389 2.6.1.16 cholest-5-en-3-yl 4,7-dichloro-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252390 2.6.1.16 cholest-5-en-3-yl 5,7-dibromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252391 2.6.1.16 cholest-5-en-3-yl 5-bromo-2-oxo-1,1',2,2',5',6',7',7'a-octahydrospiro[indole-3,3'-pyrrolizine]-2'-carboxylate - 252392 2.6.1.16 Congo red CR, affects the growth, morphology, and activity of glucosamine-6-phosphate synthase in human pathogenic fungus Sporothrix schenckii. Under conditions of yeast development, 0.015 mM CR abolishes conidia germination, but when yeast cells are first obtained in the absence of the dye and then post-incubated in its presence, yeasts rapidly differentiate into mycelial cells. On the other hand, under conditions of mycelium development, 0.150 mM CR do not affect conidia germination, but filamentous cells undergo structural changes characterized by a distorted cell wall contour, the loss of polarity and the formation of red-pigmented, hyphal globose structures. Under these conditions, CR also induces a significant and transient increase in the activity of GlcN-6-P synthase, an essential enzyme in cell wall biogenesis 7171 2.6.1.16 D-glucitol 6-phosphate competitive with respect to D-fructose 6-phosphate 22020 2.6.1.16 D-glucosamine 6-phosphate negative feedback-regulation at post-transcriptional level. The biological function of small RNA GlmZ is to positively control the enzyme's mRNA in response to D-glucosamine 6-phosphate concentrations. YhbJ, a gene of the rpoN operon, negatively regulates GlmZ 501 2.6.1.16 D-glucosamine-6-phosphate 1 mM, about 50% loss of activity 12491 2.6.1.16 dihydroxyacetone weak 620 2.6.1.16 dihydroxyacetone phosphate weak 278 2.6.1.16 DL-delta-1-pyrroline-5-carboxylate competitive with respect to L-glutamine 51635 2.6.1.16 ethyl 2-[2-(3-bromophenyl)-3-[(4-fluorophenyl)carbonyl]-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrol 1-yl]-4-methyl-1,3-thiazole-5-carboxylate 70% inhibition at 0.1 mM 135487 2.6.1.16 ethyl 2-[3-[(4-fluorophenyl)carbonyl]-4-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydro-1H pyrrol-1-yl]-4-methyl-1,3-thiazole-5-carboxylate 70% inhibition at 0.1 mM 135488 2.6.1.16 fructose 1,6-diphosphate weak 295 2.6.1.16 glyceraldehyde 3-phosphate 50% inhibition at 0.2 mM 574 2.6.1.16 glycolaldehyde weak 604 2.6.1.16 Glyoxal 50% inhibition at 0.03 mM 1444 2.6.1.16 iodoacetamide irreversible inhibition 67 2.6.1.16 iodoacetamide - 67 2.6.1.16 iodoacetate - 93 2.6.1.16 L-2,3-diaminopropanoic acid - 33180 2.6.1.16 L-alpha-glycerophosphate weak 4023 2.6.1.16 L-ascorbic acid - 974 2.6.1.16 luteolin - 436 2.6.1.16 Mercuric chloride 84% inhibition at 1 mM 5577 2.6.1.16 methyl (2E)-4-([(2S)-2,3-diamino-3-oxopropyl]amino)-4-oxobut-2-enoate - 209125 2.6.1.16 methyl (2E)-4-([(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino)-4-oxobut-2-enoate - 209126 2.6.1.16 methylglyoxal 50% inhibition at 0.01 mM, non competitive 322 2.6.1.16 methylglyoxal inhibits preincubated enzyme less profoundly than the untreated enzyme 322 2.6.1.16 additional information no inhibition by 0.1 mM c3, 4, 6, 9, 12, 13 2 2.6.1.16 additional information a series of covalent cholesterol-spiro pyrrolidine/pyrrolizidine heterocyclic hybrids possessing biologically active oxindole, indanedione, and acenaphthylene-1-one are synthesized as enzyme inhibitors by the reaction of C3-beta-cholesteroalacrylate with heterocyclic di- and tri-ketones, the compounds are obtained as a single isomer in good yield through a stereo- and regioselective 1,3-dipolar cycloaddition methodology, method overview. Analysis of in vitro antibacterial activity, and inhibitory activity against highly pathogenic Gram-positive and Gram-negative bacteria. Automated in silico molecular docking analysis of cadidates in order to validate their effective orientation as inhibitors bound in the active site of glucosamine-6-phosphate synthase (1XFF) enzyme 2 2.6.1.16 additional information synthesis of naringenin derivatives with potent glucosamine-6-phosphate synthase inhibitory capacities and antioxidant, antimicrobial, and preservative efficacy. Molecular docking and in silico ADMET analysis, structure-activity relationship studies, overview. MIC values for growth inhibition of the cells 2 2.6.1.16 N-acetyl-2-amino-2-deoxy-D-glucitol-6-phosphate - 62537 2.6.1.16 N-ethylmaleimide irreversible inhibition 49 2.6.1.16 N-ethylmaleimide 78% inhibition at1 mM 49 2.6.1.16 N-iodoacetylglucosamine 6-phosphate D-fructose 6-phosphate protects 113955 2.6.1.16 N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid L-glutamine and some analogs protect 8157 2.6.1.16 N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid - 8157 2.6.1.16 N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid acts as active-site-directed inactivator blocking the N-terminal, glutamine-binding domain of the enzyme; inhibitor of the glutamine binding site 8157 2.6.1.16 N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid selective 8157 2.6.1.16 N3-bromoacetyl-L-2,3-diaminopropanoic acid competitive with respect to L-glutamine 16946 2.6.1.16 N3-bromoacetyl-L-2,3-diaminopropanoic acid inhibitor of the glutamine binding site 16946 2.6.1.16 N3-chloroacetyl-L-2,3-diaminopropanoic acid competitive with respect to L-glutamine 22138 2.6.1.16 N3-fumaramoyl-L-2,3-diaminopropanoic acid - 33207 2.6.1.16 N3-fumaroyl-L-2,3-diaminopropanoic acid - 20424 2.6.1.16 N3-fumarylcarboxyamido-L-2,3-diaminopropionic acid competitive with L-glutamine 31057 2.6.1.16 N3-fumarylcarboxyamido-L-2,3-diaminopropionic acid - 31057 2.6.1.16 N3-iodoacetyl-L-2,3-diaminopropanoic acid competitive with respect to L-glutamine 22139 2.6.1.16 N3-L-trans-epoxysuccinamoyl-L-2,3-diaminopropanoic acid inhibitor of the glutamine binding site 135486 2.6.1.16 N4-(4-Methoxyfumaroyl)-L-2,4-diaminobutanoic acid - 94415 2.6.1.16 naringenin - 586 2.6.1.16 p-chloromercuribenzoate - 43 2.6.1.16 p-chloromercuribenzoate 84% inhibition at 0.1 mM 43 2.6.1.16 p-hydroxymercuribenzoate - 98 2.6.1.16 pyridoxamine-5'-phosphate - 30370 2.6.1.16 Tolbutamide 80% inhibition at 2 mg/ml 9280 2.6.1.16 UDP-glucose - 64 2.6.1.16 UDP-N-acetyl-alpha-D-glucosamine - 1424 2.6.1.16 UDP-N-acetylglucosamine competitive with respect to D-fructose 6-phosphate, non-competitive with respect to L-glutamine 383 2.6.1.16 UDP-N-acetylglucosamine weak 383 2.6.1.16 UDP-N-acetylglucosamine partial 383 2.6.1.16 UDP-N-acetylglucosamine 40% inhibition at 1 mM 383 2.6.1.16 UDP-N-acetylglucosamine competitive inhibitor with respect to D-fructose 6-phosphate 383 2.6.1.16 UDP-N-acetylglucosamine feed-back inhibition 383 2.6.1.16 UDP-N-acetylglucosamine - 383 2.6.1.16 UDP-N-acetylglucosamine maximum inhibition at 1 mM 383 2.6.1.16 uridine 5'-diphospho-N-acetyl-D-glucosamine - 19704 2.6.1.16 uridine 5'-diphospho-N-acetylglucosamine - 77419